Viholabs
The Biotechnology Platform That Is Mapping the Gut–Brain Axis to Dominate the Future of Wellness.
The GLP-1 Revolution Created a Void
Opportunity
Our Solution: Metabolic Synchronization
The Complete Solution to Control 100% of the Market
We Don’t Sell a Product, We Build a Value Ecosystem
AI
Growth Engine and Data
Competitive Moat and High-Value Assets
Rapid Product Launch
Our Roadmap to Unicorn Status
Financial Projections: The Path to +100M€
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Revenue | 6 | 12 | 25 | 55 | 110 |
| Gross Profit | 4 | 8 | 17 | 37 | 74 |
| EBITDA | -0.5 | 1 | 3 | 11 | 28 |
- Growth: Expansion to 40+ countries and annual launch of 2+ new “Lifestyle” products
- Gross Margin: Sustained at ~67% thanks to supply chain optimization
- Profitability: Initial investment with scaling to 25% margin in Year 5
The founding alliance that makes the difference
Co-Architect of Strategies at Novo Nordisk. The only one who can anticipate the market because was there when it was created.
30 years of experience bringing health and biotechnology innovations to international markets. The architect of our market dominance.
Former Director of the Spanish Agency of Health Technologies. Our guarantee of access and compliance in the complex global health landscape.
The Perfect Storm: The Convergence of Four Unrepeatable Forces
GLP-1s created a €100B wave and educated the world, but can only serve 1%. We’re designed to absorb the remaining 99%.
First to launch a holistic, safe, and accessible metabolic control solution at global scale. The window to capture leadership is NOW.
Our AI ecosystem converts today’s revenue into a data moat & IP for the future — the valuation multiplier.
With a team that was inside the mind of Novo Nordisk, we don’t have to guess the market’s future; we come from it.
Partner with VihoLabs to unlock safe, accessible, and sustainable metabolic control for the 99%.
Request information by email